<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124368</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-201</org_study_id>
    <secondary_id>2016-003525-42</secondary_id>
    <nct_id>NCT03124368</nct_id>
  </id_info>
  <brief_title>A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN</brief_title>
  <official_title>A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Participants With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to determine whether ACH-0144471 (also known as&#xD;
      danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants&#xD;
      with low C3 levels due to either C3G or IC-MPGN.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Actual">January 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Serum C3 levels were measured by conventional Roche immunoturbidimetric assay method.&#xD;
Change from Baseline = Serum C3 levels on Day 15 - Baseline Serum C3 levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline In Plasma Intact C3 Level On Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Plasma Intact C3 level were measured by a novel multiplex assay method. Change from Baseline = Plasma Intact C3 levels on Day 15 - Baseline Plasma Intact C3 levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Total Complement Classical Pathway (CP) Activity On Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>CP activity was measured in serum by the DiaSorin Complement Activation Enzyme (CAE) functional immunoassay method, which measures terminal complement complex formation following activation. Results are expressed in CAE units which are calculated relative to previously established CAE activity of a positive control serum.&#xD;
Change from Baseline = Total Complement CP Activity on Day 14 - Baseline Total Complement CP Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Total Complement Alternative Pathway (AP) Functional Activity (AP Wieslab) On Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>AP functional activity was measured in serum by the Wieslab functional immunoassay method, which measures terminal complement complex (TCC) formation following AP-specific activation. Results are expressed as percent TCC production relative to a positive control serum.&#xD;
Change from Baseline = Total Complement AP Functional Activity on Day 15 - Baseline Total Complement AP Functional Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Achieving Peak Serum C3 Levels</measure>
    <time_frame>From The First Day Of Dosing through Day 14</time_frame>
    <description>Serial serum samples were collected on Days 1, 7, and 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Treatment-emergent Adverse Events (TEAEs), And Adverse Events (AEs) Leading To Discontinuation</measure>
    <time_frame>Up to Day 49</time_frame>
    <description>An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve From Time Of Administration To 8 Hours Postdose (AUC0-8)</measure>
    <time_frame>Days 1 and 7</time_frame>
    <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Days 1 and 7</time_frame>
    <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time To Maximum Concentration (Tmax)</measure>
    <time_frame>Days 1 and 7</time_frame>
    <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Bb Fragment Of Complement Factor B (Bb) At Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Plasma Bb was measured by enzyme-linked immunosorbent assay (ELISA).&#xD;
Change from Baseline = Complement Bb on Day 15 - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Soluble Terminal Complement Complex (sC5b-9) At Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Plasma sC5b-9 was measured by ELISA.&#xD;
Change from Baseline = sC5b-9 on Day 15 - Baseline sC5b-9</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>C3 Glomerulonephritis</condition>
  <condition>Dense Deposit Disease</condition>
  <condition>C3 Glomerulopathy</condition>
  <condition>Immune Complex Mediated Membranoproliferative Glomerulonephritis</condition>
  <condition>Membranoproliferative Glomerulonephritis Types I, II, and III</condition>
  <arm_group>
    <arm_group_label>Group 1: Danicopan 100 mg TID (Sentinel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Danicopan up to 200 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).</description>
    <arm_group_label>Group 1: Danicopan 100 mg TID (Sentinel)</arm_group_label>
    <arm_group_label>Group 2: Danicopan up to 200 mg TID</arm_group_label>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
    <other_name>ACH-0144471</other_name>
    <other_name>ALXN2040</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must have had clinical diagnosis of C3G (C3 glomerulonephritis or dense deposit&#xD;
             disease, the 2 types of C3G) or idiopathic IC-MPGN by renal biopsy for at least 3&#xD;
             months prior to dosing, with the pathologic diagnosis verified by a review of the&#xD;
             renal biopsy by the study central pathologist&#xD;
&#xD;
          -  C3 must have been &lt;50% of the lower limit of normal&#xD;
&#xD;
          -  C4 complement protein (C4) must have been &gt;90% of the lower limit of normal&#xD;
&#xD;
          -  Must have been willing to comply with study-specific vaccination requirements for&#xD;
             Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis strains&#xD;
             A, C, W, and Y&#xD;
&#xD;
          -  Negative pregnancy test for females prior to dosing and throughout the study&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of a major organ transplant (for example, heart, lung, kidney, liver) or&#xD;
             hematopoietic stem cell/marrow transplant. Individuals receiving renal replacement&#xD;
             therapy were also excluded&#xD;
&#xD;
          -  Evidence of monoclonal gammopathy of unclear significance, infections, malignancy,&#xD;
             autoimmune diseases, or other conditions to which C3G or IC-MPGN may have been&#xD;
             secondary&#xD;
&#xD;
          -  Estimated glomerular filtration rate (using Modification of Diet in Renal Disease&#xD;
             equation) &lt;45 milliliters/minute/1.73 square meters at the time of Screening or at any&#xD;
             time over the preceding 4 weeks&#xD;
&#xD;
          -  Receipt of eculizumab at any dose or interval within the past 75 days prior to dosing&#xD;
&#xD;
          -  Use of tacrolimus or cyclosporine within 2 weeks of the first dose of danicopan&#xD;
&#xD;
          -  History of febrile illness, a body temperature &gt;38°Celsius, or other evidence of a&#xD;
             clinically significant active infection, within 14 days prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  History of meningococcal infection, or a first-degree relative or household contact&#xD;
             with a history of meningococcal infection&#xD;
&#xD;
          -  Females who were pregnant, nursing, or planning to become pregnant during the study or&#xD;
             within 90 days of study drug administration or participants with a female partner who&#xD;
             was pregnant, nursing, or planning to become pregnant during the study or within 90&#xD;
             days of study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <disposition_first_submitted>November 5, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 5, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 7, 2019</disposition_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>factor D</keyword>
  <keyword>FD</keyword>
  <keyword>alternative pathway</keyword>
  <keyword>complement mediated disease</keyword>
  <keyword>idiopathic MPGN</keyword>
  <keyword>MPGN Type I</keyword>
  <keyword>MPGN Type II</keyword>
  <keyword>MPGN Type III</keyword>
  <keyword>Primary MPGN</keyword>
  <keyword>MCGN</keyword>
  <keyword>Mesangiocapillary Glomerulonephritis</keyword>
  <keyword>C3 Glomerulopathy</keyword>
  <keyword>C3G</keyword>
  <keyword>Membranoproliferative Glomerulonephritis</keyword>
  <keyword>C3GN</keyword>
  <keyword>Dense Deposit Disease</keyword>
  <keyword>DDD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03124368/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03124368/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 5 study centers total in Australia, Belgium, and The Netherlands. Only 3 study centers, 1 in each country, treated participants.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
          <description>Participants received 100 milligrams (mg) of danicopan three times daily (TID) during the Treatment Period.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Danicopan up to 200 mg TID</title>
          <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of danicopan.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
          <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Danicopan up to 200 mg TID</title>
          <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.50" spread="7.85"/>
                    <measurement group_id="B2" value="30.00" spread="12.68"/>
                    <measurement group_id="B3" value="28.50" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15</title>
        <description>Serum C3 levels were measured by conventional Roche immunoturbidimetric assay method.&#xD;
Change from Baseline = Serum C3 levels on Day 15 - Baseline Serum C3 levels</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15</title>
          <description>Serum C3 levels were measured by conventional Roche immunoturbidimetric assay method.&#xD;
Change from Baseline = Serum C3 levels on Day 15 - Baseline Serum C3 levels</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.060"/>
                    <measurement group_id="O2" value="0.56" spread="0.230"/>
                    <measurement group_id="O3" value="0.48" spread="0.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.060"/>
                    <measurement group_id="O2" value="0.70" spread="0.350"/>
                    <measurement group_id="O3" value="0.58" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.000"/>
                    <measurement group_id="O2" value="0.14" spread="0.140"/>
                    <measurement group_id="O3" value="0.11" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline In Plasma Intact C3 Level On Day 15</title>
        <description>Plasma Intact C3 level were measured by a novel multiplex assay method. Change from Baseline = Plasma Intact C3 levels on Day 15 - Baseline Plasma Intact C3 levels</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Plasma Intact C3 Level On Day 15</title>
          <description>Plasma Intact C3 level were measured by a novel multiplex assay method. Change from Baseline = Plasma Intact C3 levels on Day 15 - Baseline Plasma Intact C3 levels</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.50" spread="0.710"/>
                    <measurement group_id="O2" value="58.25" spread="47.910"/>
                    <measurement group_id="O3" value="52.00" spread="38.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.30" spread="17.390"/>
                    <measurement group_id="O2" value="33.50" spread="9.040"/>
                    <measurement group_id="O3" value="40.43" spread="15.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.80" spread="18.100"/>
                    <measurement group_id="O2" value="-24.75" spread="50.970"/>
                    <measurement group_id="O3" value="-11.57" spread="45.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Total Complement Classical Pathway (CP) Activity On Day 14</title>
        <description>CP activity was measured in serum by the DiaSorin Complement Activation Enzyme (CAE) functional immunoassay method, which measures terminal complement complex formation following activation. Results are expressed in CAE units which are calculated relative to previously established CAE activity of a positive control serum.&#xD;
Change from Baseline = Total Complement CP Activity on Day 14 - Baseline Total Complement CP Activity</description>
        <time_frame>Baseline, Day 14</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of Danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Total Complement Classical Pathway (CP) Activity On Day 14</title>
          <description>CP activity was measured in serum by the DiaSorin Complement Activation Enzyme (CAE) functional immunoassay method, which measures terminal complement complex formation following activation. Results are expressed in CAE units which are calculated relative to previously established CAE activity of a positive control serum.&#xD;
Change from Baseline = Total Complement CP Activity on Day 14 - Baseline Total Complement CP Activity</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>CAE unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" spread="21.210"/>
                    <measurement group_id="O2" value="91.00" spread="41.370"/>
                    <measurement group_id="O3" value="71.00" spread="45.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.50" spread="23.330"/>
                    <measurement group_id="O2" value="96.75" spread="23.680"/>
                    <measurement group_id="O3" value="78.33" spread="35.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" spread="2.120"/>
                    <measurement group_id="O2" value="5.75" spread="34.250"/>
                    <measurement group_id="O3" value="7.33" spread="26.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Total Complement Alternative Pathway (AP) Functional Activity (AP Wieslab) On Day 15</title>
        <description>AP functional activity was measured in serum by the Wieslab functional immunoassay method, which measures terminal complement complex (TCC) formation following AP-specific activation. Results are expressed as percent TCC production relative to a positive control serum.&#xD;
Change from Baseline = Total Complement AP Functional Activity on Day 15 - Baseline Total Complement AP Functional Activity</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Total Complement Alternative Pathway (AP) Functional Activity (AP Wieslab) On Day 15</title>
          <description>AP functional activity was measured in serum by the Wieslab functional immunoassay method, which measures terminal complement complex (TCC) formation following AP-specific activation. Results are expressed as percent TCC production relative to a positive control serum.&#xD;
Change from Baseline = Total Complement AP Functional Activity on Day 15 - Baseline Total Complement AP Functional Activity</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>percentage of activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.350" spread="10.508"/>
                    <measurement group_id="O2" value="31.073" spread="19.779"/>
                    <measurement group_id="O3" value="23.498" spread="19.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.635" spread="2.3122"/>
                    <measurement group_id="O2" value="0.993" spread="1.1101"/>
                    <measurement group_id="O3" value="1.207" spread="1.3852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.715" spread="8.1954"/>
                    <measurement group_id="O2" value="-30.08" spread="19.176"/>
                    <measurement group_id="O3" value="-22.29" spread="19.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Achieving Peak Serum C3 Levels</title>
        <description>Serial serum samples were collected on Days 1, 7, and 14.</description>
        <time_frame>From The First Day Of Dosing through Day 14</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Achieving Peak Serum C3 Levels</title>
          <description>Serial serum samples were collected on Days 1, 7, and 14.</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.12"/>
                    <measurement group_id="O2" value="10.5" spread="4.43"/>
                    <measurement group_id="O3" value="7.8" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Treatment-emergent Adverse Events (TEAEs), And Adverse Events (AEs) Leading To Discontinuation</title>
        <description>An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Up to Day 49</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Treatment-emergent Adverse Events (TEAEs), And Adverse Events (AEs) Leading To Discontinuation</title>
          <description>An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs ≥Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve From Time Of Administration To 8 Hours Postdose (AUC0-8)</title>
        <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
        <time_frame>Days 1 and 7</time_frame>
        <population>All participants receiving at least 1 dose of danicopan who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan 150 mg TID</title>
            <description>Participants received 150 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Danicopan 200 mg TID</title>
            <description>Participants received 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve From Time Of Administration To 8 Hours Postdose (AUC0-8)</title>
          <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
          <population>All participants receiving at least 1 dose of danicopan who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="871" spread="38.1"/>
                    <measurement group_id="O2" value="2060"/>
                    <measurement group_id="O3" value="1640" spread="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1120" spread="44.4"/>
                    <measurement group_id="O2" value="2470"/>
                    <measurement group_id="O3" value="1760" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Maximum Plasma Concentration (Cmax)</title>
        <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
        <time_frame>Days 1 and 7</time_frame>
        <population>All participants receiving at least 1 dose of danicopan who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan 150 mg TID</title>
            <description>Participants received 150 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Danicopan 200 mg TID</title>
            <description>Participants received 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Plasma Concentration (Cmax)</title>
          <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
          <population>All participants receiving at least 1 dose of danicopan who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" spread="6.75"/>
                    <measurement group_id="O2" value="563"/>
                    <measurement group_id="O3" value="427" spread="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" spread="41.2"/>
                    <measurement group_id="O2" value="579"/>
                    <measurement group_id="O3" value="385" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Time To Maximum Concentration (Tmax)</title>
        <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
        <time_frame>Days 1 and 7</time_frame>
        <population>All participants receiving at least 1 dose of danicopan who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan 150 mg TID</title>
            <description>Participants received 150 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Danicopan 200 mg TID</title>
            <description>Participants received 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Time To Maximum Concentration (Tmax)</title>
          <description>Serial blood samples were collected at 0, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 hours post-dose on Days 1 and 7.</description>
          <population>All participants receiving at least 1 dose of danicopan who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.50" upper_limit="2.50"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.50" upper_limit="2.50"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Bb Fragment Of Complement Factor B (Bb) At Day 15</title>
        <description>Plasma Bb was measured by enzyme-linked immunosorbent assay (ELISA).&#xD;
Change from Baseline = Complement Bb on Day 15 - Baseline</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Bb Fragment Of Complement Factor B (Bb) At Day 15</title>
          <description>Plasma Bb was measured by enzyme-linked immunosorbent assay (ELISA).&#xD;
Change from Baseline = Complement Bb on Day 15 - Baseline</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.789" spread="1.2116"/>
                    <measurement group_id="O2" value="1.229" spread="0.4729"/>
                    <measurement group_id="O3" value="1.416" spread="0.7152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.511" spread="0.9781"/>
                    <measurement group_id="O2" value="0.622" spread="0.3349"/>
                    <measurement group_id="O3" value="0.918" spread="0.6854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.278" spread="0.2335"/>
                    <measurement group_id="O2" value="-0.607" spread="0.1790"/>
                    <measurement group_id="O3" value="-0.497" spread="0.2430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Soluble Terminal Complement Complex (sC5b-9) At Day 15</title>
        <description>Plasma sC5b-9 was measured by ELISA.&#xD;
Change from Baseline = sC5b-9 on Day 15 - Baseline sC5b-9</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
            <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Danicopan up to 200 mg TID</title>
            <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All participants who received at least 1 dose of danicopan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Soluble Terminal Complement Complex (sC5b-9) At Day 15</title>
          <description>Plasma sC5b-9 was measured by ELISA.&#xD;
Change from Baseline = sC5b-9 on Day 15 - Baseline sC5b-9</description>
          <population>All participants who received at least 1 dose of danicopan and who had a baseline measurement and at least 1 measurement during the treatment period.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1002.0" spread="684.4794"/>
                    <measurement group_id="O2" value="613.750" spread="225.2397"/>
                    <measurement group_id="O3" value="743.167" spread="405.3874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1105.5" spread="622.9611"/>
                    <measurement group_id="O2" value="563.850" spread="302.4446"/>
                    <measurement group_id="O3" value="744.400" spread="459.0596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.500" spread="61.5183"/>
                    <measurement group_id="O2" value="-49.900" spread="237.1917"/>
                    <measurement group_id="O3" value="1.233" spread="201.9602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After the first dose of study medication (following Day 0) through the follow-up visit at Day 49.</time_frame>
      <desc>[Not specified]</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Danicopan 100 mg TID (Sentinel)</title>
          <description>Participants received 100 mg of danicopan TID during the Treatment Period.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Danicopan up to 200 mg TID</title>
          <description>Participants received not more than 200 mg of danicopan TID during the Treatment Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Crepitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size of the study was based on very limited clinical cases of C3G and IC-MPGN and the exploratory nature of this study to evaluate the effectiveness of danicopan.&#xD;
Plasma intact C3 values should be regarded with caution. Plasma intact C3 values were generated using a new multiplex assay method with limited historical experience, and internal studies have suggested this new assay is subject to unexplained experimental variation arising during sample preparation and handling.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alexion Pharmaceuticals Inc.</name_or_title>
      <organization>Alexion Pharmaceuticals Inc.</organization>
      <phone>855-752-2356</phone>
      <email>clinicaltrials@alexion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

